|
|
|
| “Oligometastatic pancreatic cancer” definition: The first step |
| Maximos Frountzas a , ∗, Dimitrios Schizas b , Stylianos Kykalos c , Konstantinos G Toutouzas a |
a First Propaedeutic Department of Surgery, Hippocration General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
b First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
c Second Department of Propaedeutic Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
∗ Corresponding author.
E-mail address: froumax@hotmail.com (M. Frountzas). |
|
|
|
|
Abstract Pancreatic ductal adenocarcinoma (PDAC) is nowadays the fourth leading cause of cancer-related death worldwide, but according to recent estimations it will become the second leading cause of cancer-related deaths in the USA up to 2030, following lung cancer. The implementation of neoadjuvant chemotherapy during recent years led to an increase of overall survival at 35 months in PDAC after R0 resection [1] . However, pancreatic cancer has a particularity that makes it a real challenge for clinicians: only 20% of patients are diagnosed early enough to have a resectable pancreatic cancer, whereas 40% of patients present with locally advanced or non-resectable disease, while the rest present with distant metastases [2] . Systemic chemotherapy plays the main role in metastatic PDAC treatment: polychemotherapy regimens such as FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) or combination of gemcitabine/nab-paclitaxel seemed to improve median overall survival from 6.8 to 11.1 months and 6.7 to 8.5 months, respectively [3] .
|
|
|
|
|
|
|
|
|
2023, Vol. 22 
